
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc demonstrated a notable increase in revenue for Q2, reaching $422,000, which is a substantial rise from $197,000 in Q1. The company is positioned for significant revenue growth, with projections estimating revenues of $1.3 million in 2025 and $4.5 million in 2026. Given its innovative Trans-Arterial Micro-Perfusion therapy platform designed for targeted cancer treatments, RenovoRx’s financial trajectory suggests a promising outlook as it addresses high unmet medical needs in oncology.
Bears say
RenovoRx Inc is operating in a challenging medical landscape, particularly with pancreatic cancer, which has an alarmingly low five-year overall survival rate of only 12%. The company reported a modest revenue of $0.3 to $0.4 million against a net loss of $2.9 million, consistently achieving an EPS of $(0.08), which aligns with the lower end of consensus estimates. Despite potential growth prospects, the financial metrics reveal a concerning picture of sustainability, with net losses and low revenue casting a negative outlook on the company’s future performance.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares